Please wait while we load the requested 10-K report or click the link below:
https://last10k.com/sec-filings/report/715446/000149315221000456/form10-k.htm
Document and Entity Information - USD ($) | 12 Months Ended | ||
|---|---|---|---|
Oct. 31, 2020 | Jan. 07, 2021 | Apr. 30, 2020 | |
| Cover [Abstract] | |||
| Entity Registrant Name | Anixa Biosciences Inc | ||
| Entity Central Index Key | 0000715446 | ||
| Document Type | 10-K | ||
| Document Period End Date | Oct. 31, 2020 | ||
| Amendment Flag | false | ||
| Current Fiscal Year End Date | --10-31 | ||
| Entity Well-known Seasoned Issuer | No | ||
| Entity Voluntary Filers | No | ||
| Entity Current Reporting Status | Yes | ||
| Entity Interactive Data Current | Yes | ||
| Entity Filer Category | Non-accelerated Filer | ||
| Entity Small Business Flag | true | ||
| Entity Emerging Growth Company | false | ||
| Entity Shell Company | false | ||
| Entity Public Float | $ 35,235,950 | ||
| Entity Common Stock, Shares Outstanding | 26,076,819 | ||
| Document Fiscal Period Focus | FY | ||
| Document Fiscal Year Focus | 2020 |
View differences made from one year to another to evaluate Anixa Biosciences Inc's financial trajectory
Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Anixa Biosciences Inc.
ANIX Annual Reports
-
10-K Annual Report January 2021
- 10-K Annual Report January 2020
- 10-K Annual Report January 2019
Rating
Learn More
Filter by Sentiment:
Filter by Category:
Filter by Subcategory:
-
Other - Other Highlight
35 The net loss attributable to noncontrolling interest, representing Wistar's 5% ownership interest in Certainty's net loss, decreased by approximately $98,000 to approximately $74,000 in fiscal year 2020, from approximately $172,000 in fiscal year 2019, as Certainty's net loss decreased.
-
Revenue - Product Highlight
Accordingly, the performance obligations from the license were satisfied and 100% of the revenue was recognized upon execution of the license agreement.
-
Revenue - Product Highlight
Accordingly, the performance obligations from these agreements were satisfied and 100% of the revenue was recognized upon the execution of the agreements.
-
Revenue - Product Highlight
Cash provided by financing activities was approximately $9,407,000, resulting from the sale of 3,854,305 shares of common stock in at-the-market equity offerings of approximately $9,266,000, the proceeds from exercise of stock options of approximately $122,000 and the proceeds from the sale of common stock pursuant to employee stock purchase plan of approximately $18,000.
-
Financial - Expense Highlight
Research and development expenses are related to the development of our cancer diagnostics and therapeutics programs and our anti-viral drug program, and decreased by approximately $1,092,000 to approximately $4,381,000 in fiscal year 2020, from approximately $5,473,000 in fiscal year 2019.
-
Financial - Expense
The decrease in Certainty's net...Read more
-
Financial - Income
Interest income decreased to approximately...Read more
-
Financial - Cash Flow
We can give no assurance...Read more
-
Financial - Cash Flow
The impairment recorded in fiscal...Read more
-
Other - Other
As a result, our cash,...Read more
-
Financial - Expense
General and administrative expenses decreased...Read more
Financial Statements, Disclosures and Schedules
Inside this 10-K Annual Report
SEC Filing Financial Summary
Excel Download
Loading SEC Filing Financial Summary...
Material Contracts, Statements, Certifications & more
Anixa Biosciences Inc provided additional information to their SEC Filing as exhibits
SEC Filing Exhibit
PDF Download
Loading SEC Filing Exhibit...
Ticker: ANIX
CIK: 715446
Form Type: 10-K Annual Report
Accession Number: 0001493152-21-000456
Submitted to the SEC: Thu Jan 07 2021 4:15:57 PM EST
Accepted by the SEC: Thu Jan 07 2021
Period: Saturday, October 31, 2020
Industry: Medical Laboratories
External Resources:
Insider Transactions
Stock Quote
Social Media
Bookmark the Permalink: https://last10k.com/sec-filings/anix/0001493152-21-000456.htm
